Sanofi (Euronext:SAN; NYSE:SNY) paid Denali Therapeutics Inc. (NASDAQ:DNLI) $125 million in cash up front to co-develop multiple receptor-interacting serine-threonine kinase 1 (RIPK1; RIP1) inhibitors to treat neurological and systemic inflammatory diseases. Sanofi will cover most of the clinical development costs, which Denali CFO Steve Krognes said will enable the biotech to expand its programs into additional indications.
Sanofi and Denali will jointly develop and commercialize the RIPK1 inhibitors for Alzheimer's disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis and other neurological indications...
BCIQ Target Profiles
Receptor-interacting serine-threonine kinase 1 (RIPK1) (RIP1)